POXEL FRANCE Profit Margin 2019-2021 | PXXLF

Current and historical gross margin, operating margin and net profit margin for POXEL FRANCE (PXXLF) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. POXEL FRANCE net profit margin as of June 30, 2021 is 0%.
POXEL FRANCE Annual Profit Margins
POXEL FRANCE Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.140B $0.008B
Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company's product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75